Adjuvant nivolumab in resected oesophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: Slovenian real-world data
References
- World Health Organization International Agency for Research on Cancer (IARC). GLOBOCAN 2020: estimated cancer incidence, mortality and prevalence worldwide in 2020. [internet]. [cited 2025 Sept 19]. Available at: http://globocan.iarc.fr
- Cancer in Slovenia 2021. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Slovenian Cancer Registry; 2024
- Obermannová R, Alsina M, Cervantes A, Leong T, Lordick F, et al; ESMO Guidelines Committee. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33: 9921004. doi: 10.1016/j.annonc.2022.07.003
- Secerov-Ermenc A, Peterlin P, Anderluh F, But-Hadzic J, Jeromen-Peressutti A, Velenik V, et al. Interobserver variation in gross tumour volume delineation of oesophageal cancer on MR, CT and PET/CT. Radiol Oncol 2024; 58: 580-7. doi: 10.2478/raon-2024-0043
- Eyck BM, van Lanschot JJB, Hulshof MCCM, van der Wilk BJ, Shapiro J, van Hagen P, et al; CROSS Study Group. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: The Randomized Controlled CROSS Trial. J Clin Oncol 2021; 39: 1995-2004. doi: 10.1200/JCO.20.03614
- Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, et al; CheckMate 577 investigators. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021; 384: 1191-203. doi: 10.1056/NEJMoa2032125. Erratum in: N Engl J Med 2023; 388: 672. doi: 10.1056/NEJMx220014
- Kelly RJ, Ajani JA, Kuzdazal J, Zander T, Can Cutsem E, Piessen G, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): first results of overall survival (OS) from CheckMate 577. [Abstract]. 2025 ASCO Annual Meeting. J Clin Onco 2025; 43(16 Suppl). doi: 10.1200/JCO.2025.43.16suppl.4000
- Kwak HV, Banks KC, Hung YY, Alcasid NJ, Susai CJ, Patel A, et al. Adjuvant immunotherapy in curative intent esophageal cancer resection patients: real-world experience within an integrated health system. Cancers (Basel) 2023; 15: 5317. doi: 10.3390/cancers15225317
- Di Maio M, Basch E, Denis F, Fallowfield LJ, Ganz PA, Howell D, et al; ESMO Guidelines Committee. The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline. Ann Oncol 2022; 33: 878-92. doi: 10.1016/j.annonc.2022.04.007
- Brunelli C, Zito E, Alfieri S, Borreani C, Roli A, Caraceni A, et al. Knowledge, use and attitudes of healthcare professionals towards patient-reported outcome measures (PROMs) at a comprehensive cancer center. BMC Cancer 2022; 22: 161. doi: 10.1186/s12885-022-09269-x
- Tarazona N, Gimeno-Valiente F, Cervantes A. Minimal residual disease in gastroesophageal adenocarcinoma: the search for the invisible. ESMO Open 2022; 7: 100547. doi: 10.1016/j.esmoop.2022.100547
- Hoeppner J, Brunner T, Schmoor C, Bronsert P, Kulemann B, Claus R, et al. Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer. N Engl J Med 2025; 392: 323-35. doi: 10.1056/NEJMoa2409408. PMID: 39842010
- Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gas-tro-oesophageal junction adenocarcinoma (FLOT4): a randomized, phase 2/3 trial. Lancet 2019; 393: 1948-57. doi: 10.1016/S0140-6736(18)32557-1
- Obermannová RL, Leong T; ESMO Guidelines Committee. ESMO Clinical Practice Guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma and metastatic squamous-cell carcinoma. ESMO Open 2025; 10: 104134. doi: 10.1016/j.esmoop.2025.104134
- Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, et al; MATTERHORN Investigators. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med 2025; 393: 217-30. doi: 10.1056/NEJMoa2503701
- Blank CU, Lucas MW, Scolyer RA, van de Wiel BA, Menzies AM, Lopez-Yurda M, et al. Neoadjuvant nivolumab and ipilimumab in resectable stage iii melanoma. N Engl J Med 2024; 391: 1696-708. doi: 10.1056/NEJMoa2402604
- Kust D, Murgic J, Vukovic P, Kruljac I, Prpic M, Zilic A, et al. Oncologist burnout syndrome in Eastern Europe: results of the multinational survey. JCO Oncol Pract 2020; 16: e366-76. doi: 10.1200/JOP.19.00470
Language: English
Submitted on: Oct 2, 2025
Accepted on: Dec 2, 2026
Published on: Apr 16, 2026
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:
© 2026 Nezka Hribernik, Rozala Arko, Gorana Gasljevic, Martina Rebersek, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.